This is a case study of when a successful phase 3 trial isn't successful enough.
News & Analysis: Shire
Here's what you need to know about the M&A mania spreading through big pharma.
Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.
Can these hot stocks keep the momentum going?
On a day benchmarks toggled between gains and losses, Takeda Pharmaceuticals announced it's considering buying Shire, and RH reported big profits.
The Soros Fund Management reportedly sold its entire holdings of Acadia Pharmaceuticals and Shire plc in the fourth quarter of 2017.
Although the biopharmaceutical giant's more recently launched products did well last quarter, sagging sales of two older drugs made investors nervous.
No joke: These giant drug stocks have PEG ratios around or below 1, showing attractive growth prospects compared to their valuations.
These drug kingpins are raking in the dough, which could lead to handsome returns for investors.
Merrimack Pharmaceuticals has key catalysts on deck that could move shares significantly in the coming year.